A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy.

A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy.

Interleukin (IL)-7 is broadly active on T-cell populations, and modified versions have been clinically evaluated for a variety of therapeutic applications, including cancer, lymphopenia, and infectious diseases; and found to be relatively well-tolerated and biologically active. Here we describe nove...

Full description

Bibliographic Details
Main Authors: William J Dower, Angie Inkyung Park, Alice V Bakker, Steven E Cwirla, Praechompoo Pongtornpipat, Blake M Williams, Prarthana Joshi, Bryan A Baxter, Michael C Needels, Ronald W Barrett
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0286834&type=printable

Internet

https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0286834&type=printable

Similar Items